/THAR
THAR Stock - Tharimmune, Inc.
Healthcare|BiotechnologyNASDAQ
$2.32+4.50%
+$0.10 (+4.50%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.62
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.55
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for THAR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.30 – $2.34
TARGET (TP)$2.67
STOP LOSS$2.13
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.45
52W High$9.08
52W Low$0.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,433,792 | $-9,455,220 | $-6,881,938 | $-3,208,017 | $-1,519,151 |
| Net Income | $-12,197,568 | $-9,319,094 | $-8,473,182 | $-2,206,643 | $-2,417,371 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-9.41 | $-107.08 | $-280.77 | $-72.81 | $-88.05 |
Company Overview
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
THARBeat Rate
25%
Last 8 quarters
Avg Surprise
-28.1%
EPS vs Estimate
Beats / Misses
2/5
1 met exactly
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q1 24
+43.2%
$-0.71vs$-1.25
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-32.0%
$-2.02vs$-1.53
Q2 25
-17.9%
$-0.99vs$-0.84
Q3 25
-10.3%
$-0.64vs$-0.58
Q4 25
+20.9%
$-0.34vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-0.43 | $-0.34 | +20.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.58 | $-0.64 | -10.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.84 | $-0.99 | -17.9% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-1.53 | $-2.02 | -32.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | — | $-2.45 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-2.42 | — | — |
Q2 2024 | May 9, 2024 | — | $-2.85 | — | — |
Q1 2024 | Mar 21, 2024 | $-1.25 | $-0.71 | +43.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-18.74 | $-41.23 | -120.0% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.16 | $-0.16 | 0.0% | = MET |
Q2 2023 | May 22, 2023 | $-0.11 | $-0.23 | -109.1% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | — | $-57.53 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-69.18 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-53.04 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-104.35 | — | — |
Q4 2021 | Dec 30, 2021 | — | $80.94 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-31.09 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-56.68 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-75.12 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-45.15 | — | — |
Latest News
Tharimmune Appoints Jacob Asbury As CFO, Effective Immediately
➖ NeutralBenzinga•Dec 12, 2025, 01:16 PM
Tharimmune Receives FDA Feedback On TH104 Prophylaxis Program Against Respiratory Depression From Fentanyl And Ultrapotent Opioids; FDA Concurred With Co.'s Proposed Modeling Plan
📈 PositiveBenzinga•Nov 13, 2025, 01:08 PM
On Nov 7, Tharimmune Appointed Sireesh Appajosyula As Interim CFO
➖ NeutralBenzinga•Nov 10, 2025, 10:41 PM
Tharimmune Entered ATM Sales Agreement Worth Up To $64.9M
📈 PositiveBenzinga•Nov 7, 2025, 11:22 AM
Tharimmune shares are trading higher after the company announced it entered into a $540 million private placement to fund the Canton Network blockchain strategy.
📈 PositiveBenzinga•Nov 3, 2025, 02:19 PM
Tharimmune Enters $540M Private Placement To Fund Canton Network Blockchain Strategy
📈 PositiveBenzinga•Nov 3, 2025, 02:10 PM
Tharimmune Increases Total Number Of Common Stock Authorized For Issuance From 250M To 1B Shares
📉 NegativeBenzinga•Oct 10, 2025, 08:24 PM
Reported August 26, 2025: Tharimmune Files Prospectus To Register ~2.46M Shares, Including PIPE And Warrant Shares
➖ NeutralBenzinga•Aug 27, 2025, 03:00 PM
Tharimmune shares are trading lower after the company announced it has entered into a $3.5 million securities purchase agreement.
➖ NeutralBenzinga•Aug 26, 2025, 02:27 PM
Tharimmune Enters $5.35M Securities Purchase Agreement
📈 PositiveBenzinga•Aug 26, 2025, 01:37 PM
Tharimmune shares are trading higher following pharmacokinetic simulation results for its lead drug candidate TH104.
📈 PositiveBenzinga•Aug 21, 2025, 05:03 PM
Tharimmune Shares Halted On Circuit Breaker To The Downside, Stock Now Up 26.74%
📈 PositiveBenzinga•Aug 21, 2025, 01:37 PM
Tharimmune shares are trading higher after the company announced results from TH104.
📈 PositiveBenzinga•Aug 20, 2025, 12:28 PM
Tharimmune Announces Results From Recent Pharmacokinetic Simulation Analysis Of Its Lead Clinical Asset, TH104, Buccal Film Formulation Of Nalmefene
➖ NeutralBenzinga•Aug 20, 2025, 12:15 PM
Frequently Asked Questions about THAR
What is THAR's current stock price?
Tharimmune, Inc. (THAR) is currently trading at $2.32 per share. The stock has moved +4.50% today.
What is the analyst price target for THAR?
No analyst price targets are currently available for this stock.
What sector is Tharimmune, Inc. in?
Tharimmune, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is THAR's market cap?
Tharimmune, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does THAR pay dividends?
No, Tharimmune, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
ADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
AIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
Explore stocks similar to THAR for comparison